ArticleBMJ open2025
Design and evaluation of the pulmonary rehabilitation programme for patients with oral and maxillofacial cancer: a randomised controlled trial protocol.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPostoperative pulmonary complications are a common and significant concern following head and neck surgeries. Patients with oral and maxillofacial cancer are particularly susceptible to reduced pulmonary function, impaired exercise capacity and diminished quality of life. Pulmonary rehabilitation (PR) has been widely validated as an effective intervention for managing respiratory diseases, improving functional capacity and enhancing health-related quality of life. However, a critical gap persists in developing PR programmes specifically tailored to the distinct physiological and functional challenges faced by patients with oral and maxillofacial cancer. This protocol introduces an innovative PR intervention uniquely designed to address these challenges, bridging the gap in current rehabilitation practices and offering a comprehensive approach to improve recovery outcomes. METHODS AND ANALYSIS: This single-blind, two-arm, randomised controlled trial will enrol 144 patients with oral and maxillofacial malignancies from a tertiary hospital in China. Participants will be randomly assigned to either the intervention group (n=72), receiving routine care alongside a tailored PR programme designed by the research team, or the control group (n=72), receiving routine care alone. The primary outcome is pulmonary function, which is assessed using pulmonary function tests. Secondary outcomes include exercise capacity, quality of life and cancer-related fatigue. Outcomes will be assessed at three time points: baseline (T0), before discharge and 2 months postdischarge (T1), allowing for evaluation of both immediate and sustained intervention effects. ETHICS AND DISSEMINATION: The trial has received ethical approval from the Ethics Committee of West China Hospital of Stomatology, Sichuan University (WCHSIRB-D-2025-025). Study findings will be disseminated through peer-reviewed journals and conference presentations. TRIAL REGISTRATION NUMBER: ChiCTR2500099236.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.